<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__http://www.childrensleukemia.org/researchgrants.html__;!!PhOWcWs!g5Af6a_-UqX8D7GUdd3Z9NQDc0DG_LA-SdGtzjzvmWBYpzE6BiVHU1cmVRJnwy5R28Ia4_8EPqvHIEMmzeo$" target="_blank">Children's Leukemia Research Association, Inc.: Research Grants</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The association welcomes applications for its Research Grant Program. Through the program, grants will be awarded to PhDs or MDs conducting promising research into leukemia in the hopes of isolating its
causes and finding a cure.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due June 30, 2020. <span style="color:red">
Med-RA deadline to receive draft documents: June 17.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.com/v3/__https://www.damonrunyon.org/for-scientists/application-guidelines/innovation__;!!PhOWcWs!g5Af6a_-UqX8D7GUdd3Z9NQDc0DG_LA-SdGtzjzvmWBYpzE6BiVHU1cmVRJnwy5R28Ia4_8EPqvH7zAwP0A$" target="_blank">Damon Runyon Cancer Research Foundation Rachleff Innovation Award</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with “high-risk/high-reward” ideas that have the potential
to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional
funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">Stage 1: $200,000 for 2-year projects, no IDC.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Stage 1 application due July 1, 2020.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents: June 18.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.com/v3/__https://www.apa.org/apf/funding/stuart-grant?tab=1__;!!PhOWcWs!g5Af6a_-UqX8D7GUdd3Z9NQDc0DG_LA-SdGtzjzvmWBYpzE6BiVHU1cmVRJnwy5R28Ia4_8EPqvHC39d38g$" target="_blank">American Psychological Foundation: Grants for Early Career Psychologists Studying Links Between Mental and Physical
Health</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The Marian R. Stuart Grant will further the research, practice, or education of an early career psychologist on the connection between mental and physical health, particularly for work that
contributes to public health. Examples include but are not limited to research-based programs that teach medical doctors counseling skills; research-based programs on the effect of behavior on health; and research-based programs on psychologists’ role in medical
settings for the benefit of patients.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">Preference will be given to psychologists working in medical schools. $20,000 for one-year projects; no IDC.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Due July 1, 2020.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents: June 18.</span></b><span style="font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Advancing Genomic Medicine Research (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-037.html__;!!PhOWcWs!g5Af6a_-UqX8D7GUdd3Z9NQDc0DG_LA-SdGtzjzvmWBYpzE6BiVHU1cmVRJnwy5R28Ia4_8EPqvH6-NfLwQ$" target="_blank">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-036.html__;!!PhOWcWs!g5Af6a_-UqX8D7GUdd3Z9NQDc0DG_LA-SdGtzjzvmWBYpzE6BiVHU1cmVRJnwy5R28Ia4_8EPqvHrMmGOVE$" target="_blank">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">These Funding Opportunity Announcements encourage applications that stimulate innovation and advance understanding of when, where, and how best to implement the use of genomic information and technologies
in clinical care. Proposed projects should be broadly applicable to genomic medicine as a field, and yield findings of significance beyond a single disease, gene, or setting. Projects are strongly encouraged to include ancestrally diverse and underrepresented
participants and populations.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due August 3, 2020; March 8, 2021; November 2, 2021; August 1, 2022; and March 13, 2023. <span style="color:red">Med-RA deadline to receive draft documents for August 3, 2020 due date: July 21.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Congressionally Directed Medical Research Programs<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/dmdrp__;!!PhOWcWs!g5Af6a_-UqX8D7GUdd3Z9NQDc0DG_LA-SdGtzjzvmWBYpzE6BiVHU1cmVRJnwy5R28Ia4_8EPqvH7yStwcM$" target="_blank">Duchenne Muscular Dystrophy Research Program</a><br>
<b>Idea Development Award</b><br>
Pre-application: August 12, 2020. Invited full application: December 7, 2020.<br>
<b>Translational Research Partnership Award</b><br>
Pre-application: August 12, 2020. Invited full application: December 7, 2020.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft pre-application documents: August 3.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/lrp__;!!PhOWcWs!g5Af6a_-UqX8D7GUdd3Z9NQDc0DG_LA-SdGtzjzvmWBYpzE6BiVHU1cmVRJnwy5R28Ia4_8EPqvHbxkStuc$" target="_blank">Lupus Research Program</a><br>
<b>Idea Award</b><br>
Pre-application (letter of intent): August 25, 2020. Application: September 23, 2020.<br>
<b>Impact Award</b><br>
Pre-application (letter of intent): August 25, 2020. Application: September 23, 2020.<br>
<b>Transformative Vision Award</b><br>
Pre-application (letter of intent): August 25, 2020. Application: September 23, 2020.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft pre-application documents: August 12.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-221.html__;!!PhOWcWs!g5Af6a_-UqX8D7GUdd3Z9NQDc0DG_LA-SdGtzjzvmWBYpzE6BiVHU1cmVRJnwy5R28Ia4_8EPqvHBcH3Wus$" target="_blank">NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The NIDA Avant-Garde Award Program for HIV/AIDS Research supports exceptionally creative scientists, who propose high-impact research that will open new areas of HIV/AIDS research in the context
of Substance Use Disorders (SUD) and/or lead to new avenues for prevention and treatment of HIV/AIDS in people who use drugs (PWUD). The term “avant-garde” refers to highly innovative ideas and/or approaches that have the potential to be transformative. Applications
responding to this FOA must propose research that is substantially different from what is currently being pursued by the investigator or others and should support the NIH HIV/AIDS Research Priorities
<a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html__;!!PhOWcWs!g5Af6a_-UqX8D7GUdd3Z9NQDc0DG_LA-SdGtzjzvmWBYpzE6BiVHU1cmVRJnwy5R28Ia4_8EPqvHoJNHrRk$">https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html</a>. The NIDA Avant-Garde award supports innovative basic, clinical and translational research that may lead to
improved therapies or preventive interventions for HIV/AIDS for PWUD; creative, new strategies to prevent HIV transmission in high-risk drug using populations; novel approaches to improve HIV and HIV-related comorbid disease outcomes; and creative approaches
to eradicating HIV and improving the lives of PWUD living with HIV in general.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Due August 13, 2020; August 13, 2021; and August 15, 2022.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents for August 13, 2020 due date: August 3.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-224.html__;!!PhOWcWs!g5Af6a_-UqX8D7GUdd3Z9NQDc0DG_LA-SdGtzjzvmWBYpzE6BiVHU1cmVRJnwy5R28Ia4_8EPqvHNvrVsTY$" target="_blank">Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The Avenir Award Program for research on Substance Use Disorders (SUD) and HIV/AIDS looks towards the future by supporting early stage investigators (ESI) proposing highly innovative studies
that address NIH HIV/AIDS Research Priorities <a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html__;!!PhOWcWs!g5Af6a_-UqX8D7GUdd3Z9NQDc0DG_LA-SdGtzjzvmWBYpzE6BiVHU1cmVRJnwy5R28Ia4_8EPqvHoJNHrRk$">
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html</a>. The Avenir Award Program will support creative individuals who wish to pursue innovative research at the nexus of SUD and HIV/AIDS. The purpose of this program is to support broad spectrum
of approaches spanning both basic and clinical research that have the potential to benefit substance using populations with or at risk for HIV/AIDS by reducing HIV incidence, optimizing therapies for HIV and SUD, reducing the impact of comorbid conditions,
and ultimately, eradicating HIV. Applications responding to this FOA must clearly describe the intersection of substance use disorders with HIV/AIDS.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Due August 13, 2020; August 13, 2021; and August 15, 2022.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents for August 13, 2020 due date: August 3.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-225.html__;!!PhOWcWs!g5Af6a_-UqX8D7GUdd3Z9NQDc0DG_LA-SdGtzjzvmWBYpzE6BiVHU1cmVRJnwy5R28Ia4_8EPqvHFiUkWuk$" target="_blank">Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">This award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the
preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow’s leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics
studies.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The Genetics or Epigenetics of Substance Use Disorders Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics
or epigenetics of addiction. These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction. Investigators outside the field of addiction interested in applying their novel approaches to
the genetics or epigenetics of addiction are encouraged to apply. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being
tomorrow’s leaders in the field of genetics or epigenetics of substance use disorders.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">October 19, 2020; October 19, 2021; and October 19, 2022.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents for October 19, 2020 due date: October 6.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-013.html__;!!PhOWcWs!g5Af6a_-UqX8D7GUdd3Z9NQDc0DG_LA-SdGtzjzvmWBYpzE6BiVHU1cmVRJnwy5R28Ia4_8EPqvHlXwjDSo$" target="_blank">Advancing HIV/AIDS Research through Computational Neuroscience FOA (R01 – Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">This funding opportunity announcement invites computational HIV/AIDS research as it relates to NIDA’s mission through collaborative research between investigators with experimental expertise
related to HIV/AIDS and those with computational proficiency, including scientists from statistics, physics, mathematics, engineering, and computer science. An R01 research project should build on well-established computational strategies (theory, models,
and methods) to investigate HIV-related neurocognitive deficits and neuropathogenesis in the context of substance use or substance use disorder.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Due November 6, 2020.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents: October 26.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-20-009.html__;!!PhOWcWs!g5Af6a_-UqX8D7GUdd3Z9NQDc0DG_LA-SdGtzjzvmWBYpzE6BiVHU1cmVRJnwy5R28Ia4_8EPqvHFF_NTIY$" target="_blank">Alcohol-HIV/AIDS Program Project Comorbidities, Coinfections, and Complications Research: Intervention
and Cross-Cutting Foundational Research (P01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">This Funding Opportunity Announcement (FOA) solicits grant applications that propose research that can be translated into interventions in order to reduce infection and transmission of HIV
in patients with alcohol use disorders.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Due November 17, 2020.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents: November 3.</span></b><span style="font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.com/v3/__https://www.nsf.gov/pubs/2019/nsf19592/nsf19592.htm__;!!PhOWcWs!g5Af6a_-UqX8D7GUdd3Z9NQDc0DG_LA-SdGtzjzvmWBYpzE6BiVHU1cmVRJnwy5R28Ia4_8EPqvHSQRiQQg$" target="_blank">NSF: Ecology and Evolution of Infectious Diseases (EEID)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The multi-agency Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, and social drivers that influence the transmission dynamics of infectious
diseases. The central theme of submitted projects must be the quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease transmission and testing mathematical or computational
models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of transmission among humans, non-human animals, and/or
plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of reservoir species or hosts; the feedback between ecological transmission and evolutionary dynamics;
and the cultural, social, behavioral, and economic dimensions of pathogen transmission. Research may be on zoonotic, environmentally-borne, vector-borne, or enteric pathogens of either terrestrial or aquatic systems and organisms, including diseases of animals
and plants, at any scale from specific pathogens to inclusive environmental systems. Proposals for research on disease systems of public health concern to developing countries are strongly encouraged, as are disease systems of concern in agricultural systems.
Investigators are encouraged to develop the appropriate multidisciplinary team, including for example, anthropologists, modelers, ecologists, bioinformaticians, genomics researchers, social scientists, economists, oceanographers, mathematical scientists, epidemiologists,
evolutionary biologists, entomologists, parasitologists, microbiologists, bacteriologists, virologists, pathologists or veterinarians, with the goal of integrating knowledge across disciplines to enhance our ability to predict and control infectious diseases.
<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Due November 18, 2020.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents: November 4.</span></b><span style="font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><span style="font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b><span style="color:#954F72">CoM’s
unofficial funding opportunities blog</span></b></a><b>.</b></span><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
</div>
</body>
</html>